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Abstract A disintegrin-like and metalloproteinase with throm-
bospondin type I motifs-1 (ADAMTS-1) is an extracellular
matrix-anchored metalloproteinase. In this study we have
demonstrated that ADAMTS-1 is able to cleave a major
cartilage proteoglycan, aggrecan. N-terminal sequencing analy-
sis of the cleavage product revealed that ADAMTS-1 cleaves the
Glu1871^Leu1872 bond within the chondroitin sulfate attachment
domain of aggrecan. In addition, deletional analysis demon-
strated that the C-terminal spacer region of ADAMTS-1 is
necessary to degrade aggrecan. These results suggest that
ADAMTS-1 may be involved in the turnover of aggrecan in
vivo. ß 2000 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
Key words: Aggrecan; Disintegrin and metalloproteinase
thrombospondin; Extracellular matrix; Cartilage degradation
1. Introduction
Disintegrin and metalloproteinases (ADAMs) represent a
new family of gene products, which show a signi¢cant se-
quence similarity to snake venom metalloproteinase and dis-
integrin [1]. ADAMs have been shown to play a role in cell^
cell interactions as well as in the ectodomain shedding of a
variety of cell-surface proteins [1^3].
ADAMTS-1 is an ADAM family protein with both a re-
prolysin type metalloproteinase domain and three thrombo-
spondin (TSP) type I motifs, which are conserved in TSP 1
and 2 [4]. The ADAMTS-1 gene was originally identi¢ed as a
gene expressed in the colon 26 cachexigenic tumor in vivo and
is mapped to mouse chromosome 16, region C3^C5 [4,5].
ADAMTS-1 consists of a proprotein, a metalloproteinase
and a disintegrin-like domain, a central TSP type I motif,
the spacing region, and the C-terminal TSP submotifs. While
the type I motifs of ADAMTS-1 are functional in terms of
binding to heparin, ADAMTS-1 itself is a secretory protein
that is incorporated into the extracellular matrix (ECM) [6].
Analyses of deletion mutants have revealed that the spacing
region of ADAMTS-1 as well as three TSP type I motifs are
responsible for its anchoring to the ECM [6]. Furthermore, its
capacity to form a covalent complex with K2-macroglobulin
indicates the metalloproteinase domain of ADAMTS-1 being
catalytically active [7]. These ¢ndings considered together,
strongly suggest that ADAMTS-1 is an active metalloprotein-
ase that is associated with the ECM. On the other hand,
recent study showed that ADAMTS-1(METH-1) has anti-an-
giogenic activity [8].
Aggrecan is a major proteoglycan found in the ECM of
articular cartilage. The core protein of aggrecan is substan-
tially modi¢ed with chondroitin sulfate (CS) and keratan sul-
fate (KS) glycosaminoglycans, which serve to hydrate the car-
tilage tissue, providing properties of compression and
elasticity [9,10]. Aggrecan comprises several segments: the
N-terminal globular domains (G1 and G2), a long central
glycosaminoglycan attachment region, and the C-terminal
globular domain (G3) [11]. Aggrecan monomers interact
with hyaluronic acid through the G1 domain to form aggre-
gates with a large molecular weight, which keeps aggrecan
within the cartilage matrix [12,13].
In cartilage destruction associated with arthritic diseases,
measurable amounts of aggrecan are lost from cartilage tissue.
This loss of aggrecan is attributed to the accelerated degrada-
tion within the interglobular domain (IGD) of aggrecan. Two
major proteolytic cleavage sites, the Asn341^Phe342 and
Glu373^Ala374 bonds, have been identi¢ed within the IGD of
aggrecan. It is known that matrix metalloproteinases (MMPs)
can cleave the Asn341^Phe342 bond, whereas the enzymes re-
sponsible for the cleavage of the Glu373^Ala374 bond, have
been termed ‘aggrecanases’ [14^18]. The degradation products
cleaved at the Glu373^Ala374 bond have been detected in car-
tilage explants and chondrocyte cultures [14^16,19,20], and in
the synovial £uids of patients with various joint diseases [21^
23]. Therefore, it has been hypothesized that aggrecanases
play an important role in the cartilage degradation of arthri-
tis. Recently, Arner and her group have shown that aggreca-
nase-1 and -2 molecules (ADAMTS-4 and -5 (-11)) are struc-
turally related to ADAMTS-1 [24,25]. However, the
proteinases involved in the turnover of aggrecan in vivo, re-
main to be fully clari¢ed.
Because our previous study suggested that the ECM asso-
ciation of ADAMTS-1 occurs through binding to sulfated
glycosaminoglycans [6], it has been hypothesized that proteo-
glycans could be the target molecules of the ADAMTS-1 met-
alloproteinase. In the present study, we examined whether
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ADAMTS-1 has the ability to cleave a major cartilage pro-
teoglycan, aggrecan.
2. Materials and methods
2.1. Cell culture and materials
HEK293 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) (Nissui, Tokyo, Japan) supplemented with 10% fetal bovine
serum, 2 mM glutamine, 100 units/ml penicillin G, and 100 Wg/ml
streptomycin. Protease inhibitors, phenylmethylsulfonyl £uoride, pep-
statin A, and N-ethylmaleimide were obtained from Sigma (St. Louis,
MO, USA). Protease-free chondroitinase ABC (from Proteus vulgaris)
and keratanase (from Pseudomonas sp.) were obtained from Seikaga-
ku Co Ltd. (Tokyo, Japan).
2.2. Construction of expression vectors and expression of recombinant
proteins
The expression vectors for the mouse ADAMTS-1 protein or its
deletion mutants, X4 and X5, were constructed using pcDNA3 (In-
vitrogen, San Diego, CA, USA) as previously described [6]. In the
present study, a (His)6-tagged sequence was added prior to the
FLAG-epitope tag at the C-terminus of each protein to facilitate
puri¢cation.
Recombinant ADAMTS-1 proteins were prepared by means of
transient expression using HEK293 cells. Brie£y, the cells grown in
10-cm dishes were transfected with the ADAMTS-1 expression vector
by means of a lipofectamine reagent (Life Technologies Inc., Gaithers-
burg, MD, USA) according to the manufacturer’s instructions. 18 h
after transfection, the cells were washed and further cultured for
2 days in serum-free DMEM medium containing soluble heparin
(5 Wg/ml).
(His)6-tagged ADAMTS-1 proteins in the culture supernatants were
puri¢ed by a HiTrap chelating column (Amersham Pharmacia Bio-
tech, Uppsala, Sweden). Brie£y, after culture supernatants supple-
mented with 20 mM HEPES (pH 7.5) and 0.5 M NaCl were applied
to the HiTrap chelating column, the column was washed with HSB
bu¡er (40 mM HEPES, pH 7.5, 1 M NaCl, 0.05% Brij 35) containing
10 mM imidazole. Recombinant ADAMTS-1 proteins were eluted
with HSB bu¡er containing 500 mM imidazole.
2.3. Aggrecan degradation assay
Aggrecan was extracted from bovine nasal cartilage with 4 M gua-
nidine hydrochloride and puri¢ed on a cesium chloride gradient cen-
trifugation according to the methods reported by Hardingham [26].
Aggrecan was incubated with recombinant ADAMTS-1 proteins
for 12 h at 37‡C in the reaction bu¡er (20 mM Tris^HCl pH 7.6,
150 mM NaCl, 5 mM CaCl2, 0.01% NaN3). After digestion with the
ADAMTS-1 proteinase, the samples were deglycosylated with chon-
droitinase ABC (0.05 unit/10 Wg proteoglycan) and keratanase (0.05
unit/10 Wg proteoglycan) for 3 h at 37‡C in the bu¡er containing 50
mM Tris^HCl, pH 8.0, 30 mM sodium acetate, 10 mM EDTA, 5 mM
phenylmethylsulfonyl £uoride, 0.36 mM pepstatin A, and 10 mM N-
ethylmaleimide. Deglycosylated samples were heated at 100‡C for
5 min in Laemmli sample bu¡er (60 mM Tris^HCl, pH 6.8, 2% so-
dium dodecyl sulfate (SDS), 5% mercaptoethanol, 10% glycerol), and
were subjected to SDS-polyacrylamide gel electrophoresis (PAGE),
followed by immunological detection.
To immunologically detect the core protein fragments, gels were
transferred onto nitrocellulose membranes and blocked overnight in
Block ACE (Dainippon Pharmaceutical Co. Ltd., Osaka, Japan). The
membranes were then incubated with antibody 2-B-6 (anti-chondroi-
tin-4-sulfate stubs generated by chondroitinase treatment) [27] (Seika-
gaku), followed by incubation with horseradish peroxidase (HRP)-
conjugated goat anti-mouse IgG polyclonal antibodies (Amersham
Pharmacia Biotech). After washing, bound HRP-conjugated antibod-
ies were detected with a chemiluminescence (ECL) system (Amersham
Pharmacia Biotech).
2.4. N-terminal sequence analysis of an aggrecan fragment
For the determination of the N-terminal sequence of the 100-kDa
aggrecan fragment, the deletion mutant X3 of ADAMTS-1 was used
for the cleavage of aggrecan. After elution from a HiTrap chelating
column as indicated above, the ADAMTS-1 X3 protein was applied
to a HiTrap heparin column (Amersham Pharmacia Biotech) equili-
brated with 25 mM Tris^HCl, pH 7.6, 0.2 M NaCl, and 0.05% Brij 35
and was eluted with the same bu¡er containing 1 M NaCl. Aggrecan
fragments produced by digestion with the ADAMTS-1-X3 proteinase
were deglycosylated with both chondroitinase ABC and keratanase
and subjected to 6% SDS^PAGE, followed by electroblotting onto
PVDF membrane. After staining with Coomassie Blue, the region
corresponding to the 100-kDa aggrecan fragment was cut out and
Fig. 1. Aggrecan cleavage by the recombinant ADAMTS-1 protein-
ase A: The recombinant ADAMTS-1 proteins were expressed as the
mature forms in the HEK293 cell expression system. Recombinant
ADAMTS-1 (lane 1) or the mutant (E386Q) (lane 2) puri¢ed with a
Ni-chelating column (see Section 2) was analyzed by Western blot-
ting with anti-FLAG M2 antibody. B: Aggrecan-cleaving assay for
ADAMTS-1. Bovine aggrecan monomer (10 Wg) was incubated with
the recombinant ADAMTS-1 protein (0.5 Wg) (lane 2) or the mu-
tant (E386Q) (0.5 Wg)(lane 3) puri¢ed with a Ni-chelating column at
37‡C for 12 h. The Ni-chelating column-bound fraction prepared
from the culture media of the control vector-transfected cells was
used for the control reaction (lane 1). After treatment with chon-
droitinase ABC and keratanase, the samples were subjected to 6%
SDS^PAGE, and the cleavage products of aggrecan were analyzed
by Western blotting using the 2-B-6 antibody. The arrow indicates
the 100-kDa fragment of the aggrecan core protein generated by the
ADAMTS-1 proteinase.
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subjected to N-terminal amino acid sequencing using Protein Se-
quencing System G1005A (Hewlett-Packard Co., CA, USA).
3. Results
3.1. Expression of recombinant ADAMTS-1 protein
To investigate the proteolytic activity of ADAMTS-1
against proteoglycan, the recombinant ADAMTS-1 protein
was prepared by means of the transient expression system
using HEK293 cells. Both the FLAG epitope tag and the
histidine tag were added at its C-terminus for detection and
rapid puri¢cation of the recombinant protein. Because
ADAMTS-1 is an ECM-anchored protease [6], heparin was
added to the culture to allow ADAMTS-1 to be released from
the ECM into the culture supernatant. Under the expression
condition employed in our study, the majority of the recombi-
nant ADAMTS-1 was produced as the processed active form
without a proprotein domain (Fig. 1A, lane 1). Therefore, the
recombinant ADAMTS-1 protein puri¢ed by the Ni-chelating
column could be directly used in the proteinase assay without
separation of the precursor form.
3.2. Aggrecan cleavage by ADAMTS-1
To examine whether ADAMTS-1 has the ability to cleave
aggrecan, the recombinant ADAMTS-1 proteinase was incu-
bated with bovine aggrecan monomer. After the deglycosyla-
tion of aggrecan with both chondroitinase ABC and kerata-
nase, the degradation products of the aggrecan core protein
were analyzed by means of Western blotting with the anti-
body 2-B-6, which recognizes chondroitin 4-sulfate stubs of
the core protein. As shown in Fig. 1B, upon incubation of the
full-length ADAMTS-1 with the aggrecan substrate, an im-
munoreactive band migrating at approximately 100-kDa was
generated (lane 2). In contrast, the control sample prepared
from the culture supernatant of the control vector-transfected
cells lacked the activity to generate the 100-kDa core fragment
(Fig. 1B, lane 1). In addition, the inclusion of 10 mM EDTA
into the reaction mixture inhibited the generation of the 100-
kDa core fragment, whereas aprotinin and leupeptin had no
inhibitory e¡ects (data not shown).
Furthermore, the metalloproteinase-inactive mutant of
ADAMTS-1, E386Q, in which the essential Glu residue in
the zinc-binding motif was converted to Gln (Fig. 1A, lane
2), lost its capacity to generate the 100-kDa fragment of ag-
grecan (Fig. 1B, lane 3), con¢rming that the metalloproteinase
activity of ADAMTS-1 is necessary for the generation of the
100-kDa fragment. These ¢ndings demonstrate that
ADAMTS-1 has the ability to cleave the aggrecan core pro-
tein.
3.3. Requirement of the spacer region for aggrecan cleaving
activity
The C-terminal half region of ADAMTS-1 consists of the
three type I motifs and the intervening spacer region, both of
which are responsible for binding to the ECM [6]. To inves-
tigate the involvement of the C-terminal domains of
ADAMTS-1 in the aggrecan cleavage, digestion was carried
out with the C-terminal deletion mutants, X3 and X4 (Fig.
2A). As shown in Fig. 2B, mutant X3, which lacks the C-
terminal TSP submotifs, retained the activity to generate the
100-kDa fragment of aggrecan (lane 3). In contrast, when
aggrecan was incubated with mutant X4, deleting both the
spacer region and the C-terminal TSP submotifs, the 2-B-6
reactive 100-kDa band was not generated (lane 4), indicating
that deletion of the spacer region of ADAMTS-1 results in a
loss of ability or a very low ability to cleave aggrecan. This
¢nding demonstrates that the spacer region in the C-terminal
Fig. 2. Requirement of the C-terminal spacer region of ADAMTS-1
for aggrecan-degrading activity. A: The domain organization of
ADAMTS-1 and construction of the C-terminal deletion mutants.
(PRO, proprotein domain; MP, metalloproteinase domain; DIS,
disintegrin-like domain; TSP, TSP type I motif; SP, the spacer re-
gion; TSP-sub, TSP submotifs). Open bars: represent the portion
present in the processed forms of wild-type and deletion mutants
with the amino acid number at the end. The aggrecan-degrading ac-
tivities of deletion mutants are summarized on the right side of the
¢gure, together with their binding capacity to ECM, which was de-
termined in our previous study [6]. B: Aggrecan-cleaving assay for
the C-terminal deletion mutants of ADAMTS-1. Bovine aggrecan
(10 Wg) was incubated with recombinant ADAMTS-1 (0.5 Wg) (lane
2), mutant U3 (0.4 Wg) (lane 3), or mutant U4 (0.3 Wg) (lane 4) at
37‡C for 12 h. After treatment with chondroitinase ABC and kera-
tanase, generation of the 100-kDa aggrecan fragment in the reaction
mixtures was monitored by Western blotting analysis using the 2-B-
6 antibody. The control reaction (lane 1) was carried out as de-
scribed in Fig. 1B.
Fig. 3. Schematic representation of the cleavage site in the bovine
aggrecan by ADAMTS-1. The gap regions in the CS attachment
domain are indicated by asterisks. CS, chondroitin sulfate attach-
ment domain; KS, keratan sulfate attachment domain.
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half is required for recognition of the aggrecan substrate by
ADAMTS-1.
3.4. N-terminal sequencing of an aggrecan fragment generated
by ADAMTS-1
In order to determine the site at which aggrecan is cleaved
by the ADAMTS-1 proteinase, the 100-kDa aggrecan core
fragment generated by ADAMTS-1 was subjected to N-ter-
minal amino acid analysis. The 100-kDa fragment yielded the
sequence L-QRP-VTYT, which corresponds to a site in the
CS attachment region starting at Leu1872. This result suggests
that the ADAMTS-1 proteinase cleaves the Glu1871^Leu1872
bond within the CS attachment region of aggrecan.
4. Discussion
ADAMTS-1 is a metalloproteinase associated with the
ECM [6,7] and is characterized by the presence of TSP type
I motifs and a potential sulfated glycosaminoglycan-binding
region. The present study has demonstrated that the
ADAMTS-1 proteinase is able to degrade a cartilage proteo-
glycan, aggrecan.
The turnover of aggrecan is an important process for main-
tenance of homeostasis of the articular cartilage matrix. Any
increase in the degradation rate or a decrease in the biosyn-
thesis of aggrecan may have pathological consequences. The
IGD between the G1 and G2 domains is sensitive to proteo-
lytic attack, and a proteolysis of the core protein within the
IGD is up-regulated under pathological conditions such as
rheumatoid arthritis and osteoarthritis. Several MMPs
(MMP-1^3,7^9,13) have been shown to cleave the Asn341^
Phe342 bond within the IGD, whereas ‘aggrecanases’ are re-
sponsible for the cleavage at the Glu373^Ala374 bond within
the IGD [14^18]. An important ¢nding in recent studies is that
both aggrecanase-1 and -2 [ADAMTS-4, and -5 (-11)], puri-
¢ed from interleukin-1-stimulated bovine nasal cartilage cul-
ture, are members of the ADAMTS family [24,25]. Aggrecan
fragments resulting from cleavage at the Glu373^Ala374 bond
are found in the synovial £uids of patients with osteoarthritis,
in£ammatory joint disease and joint injury [21^23]. These ob-
servations suggest that ‘aggrecanases’ are involved in the deg-
radation of aggrecan in various joint diseases.
We found that a 100-kDa fragment is generated by aggre-
can cleavage by the ADAMTS-1 proteinase. Detection of this
100-kDa fragment by the 2-B-6 antibody suggests that it is
derived from the CS attachment domain of aggrecan. Further-
more, N-terminal sequencing of the fragment revealed that the
ADAMTS-1 proteinase cleaves the Glu1871^Leu1872 bond
within the CS attachment domain (Fig. 3). To date, it has
been shown that, in addition to two major proteolytic cleav-
age sites within the IGD, proteolysis of aggrecan in vivo also
occurs within the CS attachment domain [15,19,22]. The pro-
teolysis within the CS attachment domain is reported in car-
tilage explant cultures treated with interleukin-1 or retinoic
acid [15,19] and in the synovial £uids from arthritis patients
[22]. Sequencing analyses revealed that these cleavage sites are
located in gap regions, which are relatively devoid of glyco-
saminoglycan chains, of the CS attachment domain. Since
these cleavage sites in the gap regions show a sequence highly
similar to that around the Glu373^Ala374 aggrecanase site, ‘ag-
grecanase’-type proteinases have been postulated to be in-
volved in the cleavage within the CS attachment domain
[28]. The ADAMTS-1 cleavage site (E1871^L1872) is located
in one of these gap regions (Fig. 3). In view of these consid-
erations, it is reasonable that ADAMTS-1 is involved in the
degradation of the CS attachment domain of aggrecan be-
cause ADAMTS-1 shows a high sequence homology to aggre-
canase-1 and -2 (ADAMTS-4 and ADAMTS-5) among the
ADAMTS family, eight members of which have been identi-
¢ed [29^32].
The aggrecan degrading ability of ADAMTS-1 deletion
mutants is consistent with their capacity to bind to ECM,
as summarized in Fig. 2A. The deletional analyses revealed
that the spacer region in the C-terminal half of ADAMTS-1 is
required both for the tight interaction with the ECM and for
the aggrecan-cleaving activity. Our previous ¢nding that the
full-length ADAMTS-1 protein is released from the ECM into
culture supernatant in the presence of soluble heparin suggests
that the spacer region of ADAMTS-1 as well as the TSP type
I motifs may interact with sulfated glycosaminoglycans in the
ECM [6]. It is therefore presumed that the spacer region of
ADAMTS-1 plays a role in the recognition of sulfated glycos-
aminoglycans, CS and/or KS of aggrecan and that such an
interaction between the spacer region of ADAMTS-1 and
glycosaminoglycan chains is necessary for the cleavage of ag-
grecan. The recent ¢nding that the deglycosylation of aggre-
can reduces the ability of aggrecanase-1 (ADAMTS-4) to
cleave the Glu373^Ala374 bond [24] supports this notion.
Further investigation is required to establish the physiolog-
ical importance of aggrecan cleavage by ADAMTS-1. In this
connection, there have been recent reports that ADAMTS-1
mRNA is detectable by RT-PCR analysis in human articular
cartilage and arthritic joint tissues [25,32]. Therefore, our ¢nd-
ing that ADAMTS-1 has aggrecan-degrading activity strongly
suggests the possibility that ADAMTS-1 plays a role in the
turnover of aggrecan in normal physiological processes and/or
the degradation of aggrecan under pathological conditions.
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